Education
About Us
Working with TipRanks
Follow Us
Charlotte's Web Holdings (TSE:CWEB)
TSX:CWEB
RESEARCH TOOLSreports
Top Page
Charlotte's Web Holdings
(TSX:CWEB)
Rating:51Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Charlotte's Web Holdings (CWEB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
$21.41M
Dividend YieldN/A
Average Volume (3M)30.34K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth-11.84%
EPS Growth20.29%
CountryCA
Employees112
SectorHealthcare
Sector Strength41
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding158,617,770
10 Day Avg. Volume13,966
30 Day Avg. Volume30,345
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.51Price Target Upside321.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Charlotte's Web Holdings Business Overview & Revenue Model
Company DescriptionCharlotte's Web Holdings, Inc. engages in farming, manufacturing, marketing, and selling hemp-derived cannabidiol (CBD) wellness products. The company's products categories include hemp extract oil tinctures, such as liquid products; gummies comprising sleep, stress, immunity, and exercise recovery products; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte's Web, CBD Medic, CBD Clinic, and Harmony Hemp brands. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds. The company distributes its products through retail outlets and health care practitioners, as well as online through its website. It has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Denver, Colorado.
How the Company Makes MoneyCharlotte's Web Holdings generates revenue primarily through the sale of its hemp-based CBD products. The company's key revenue streams include direct-to-consumer sales via its e-commerce platform and retail sales through a broad network of retail partners, including health food stores, pharmacies, and wellness shops. Additionally, Charlotte's Web has established partnerships and distribution agreements that help expand its reach and market presence. The company's earnings are significantly influenced by consumer demand for natural wellness solutions, regulatory changes in the CBD industry, and its ability to maintain high-quality product standards.
Charlotte's Web Holdings Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q4-2024)
| % Change Since: -4.00%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted several positive developments, including a return to quarterly revenue growth, successful product expansion, and significant cost reductions. However, ongoing challenges, such as a year-over-year revenue decline, reduced gross margins, and regulatory hurdles, were also evident. The company is optimistic about its strategic initiatives and future growth, yet it acknowledges the need to address current headwinds.Q4-2024 Updates
Positive Updates
Return to Consecutive Quarterly Revenue Growth
Achieved consecutive quarterly revenue growth throughout 2024, marking a pivotal year for Charlotte's Web after years of decline.
Successful Launch of New E-commerce Platform
The new e-commerce platform led to a 20% reduction in shopping cart abandonment, improving conversion rates significantly.
Expansion of Product Offerings
Successful introduction of functional mushroom gummies, expanding into the mushroom wellness market valued at over $200 million per year, with new products soon available on Amazon.
Significant Cost Reduction Initiatives
Achieved an $8 million reduction in SG&A expenses in Q4, marking a 43.3% decrease year-over-year.
Milestone in Botanical Drug Development
DeFloria's IND application was accepted by the FDA for Phase II clinical trials, representing a potential long-term revenue opportunity.
Strategic Retail Partnerships
Expanded retail partnership with Walmart and initial sales success with Chewy.com, enhancing market presence.
Negative Updates
Decline in Year-over-Year Revenue
Net revenue was $12.7 million in Q4, down 20% from the prior year, reflecting broader category headwinds.
Reduced Gross Margin
Q4 gross profit margin decreased to 40.2%, down 15.8 basis points compared to Q4 2023 due to holiday promotions and shipping inefficiencies.
Continued Net Loss
Reported a Q4 net loss of $3.4 million, albeit a reduction compared to the previous year.
Regulatory Challenges in Retail
State-level restrictions impacted retail performance, highlighting the need for federal regulations.
Company Guidance
During the Charlotte's Web Holdings Inc. fourth quarter conference call, the company highlighted several key metrics and strategic initiatives aimed at driving future growth. The company reported a net revenue of $12.7 million for the quarter, reflecting a 20% year-over-year decline but showing modest quarter-over-quarter growth. The gross profit for Q4 was $5.1 million, with a margin of 40.2%, impacted by holiday promotions and shipping inefficiencies. However, the company achieved significant cost reductions, with SG&A expenses dropping by 43.3% to $10.6 million. The adjusted EBITDA was positive at $0.3 million, marking a $6.2 million improvement from the previous year. For the full fiscal year, total revenue stood at $49.7 million, down 21.4% year-over-year, while the gross profit before inventory provision was $25.4 million, representing 51.1% of net revenue. The company ended the year with $22.6 million in cash reserves, positioning it for growth in 2025. Key strategic moves included the expansion into the functional mushroom market and a rebranding initiative to unify its product portfolio. Additionally, Charlotte's Web is poised to benefit from its collaboration with DeFloria, which received FDA acceptance for Phase II clinical trials, potentially opening new revenue streams.Charlotte's Web Holdings Financial Statement Overview
Summary
Charlotte's Web Holdings is experiencing significant financial challenges, marked by declining revenues, profitability issues, and increasing financial risk due to higher leverage. Continued negative cash flows and strained margins suggest potential difficulties in sustaining operations without strategic improvements.Income Statement
The company has faced declining revenues over the years, with a significant drop in the most recent year. Gross profit margin has also deteriorated from 54% in 2021 to 43% in 2024, indicating pressure on profitability. The net profit margin remained negative, reflecting ongoing losses. Despite efforts, EBIT and EBITDA margins remain negative, indicating operational challenges.45
Neutral
Balance Sheet
The debt-to-equity ratio increased from 0.09 in 2021 to 2.19 in 2024, suggesting a significant rise in leverage. The equity ratio dropped from 76% in 2021 to 24% in 2024, indicating reduced financial stability. Return on equity remains negative, highlighting profitability issues. The balance sheet reflects increasing financial risk due to higher debt levels.50
Neutral
Cash Flow
Operating cash flow has remained negative, with free cash flow worsening over the period. The free cash flow to net income ratio is negative due to ongoing losses. The operating cash flow to net income ratio is also negative, reflecting cash flow challenges. The company faces difficulties in generating positive cash flow, which could impact its ability to fund operations.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 49.67M | 63.16M | 74.14M | 96.09M | 95.23M | Gross Profit |
| 21.26M | 35.57M | 19.41M | 48.59M | 52.26M | EBIT |
| -31.99M | -40.61M | -50.65M | 39.52M | -52.47M | EBITDA |
| -22.01M | -24.90M | -41.68M | -38.03M | -42.53M | Net Income Common Stockholders |
| -29.85M | -23.80M | -59.31M | -137.72M | -47.19M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 22.62M | 47.82M | 66.96M | 19.49M | 52.80M | Total Assets |
| 113.44M | 152.55M | 187.64M | 171.51M | 310.88M | Total Debt |
| 59.34M | 60.44M | 57.63M | 22.60M | 23.36M | Net Debt |
| 36.72M | 12.62M | -9.33M | 3.11M | -29.45M | Total Liabilities |
| 86.36M | 96.99M | 110.14M | 41.07M | 56.65M | Stockholders Equity |
| 27.09M | 55.56M | 77.50M | 130.45M | 254.23M |
| Cash Flow | Free Cash Flow | |||
| -25.11M | -19.08M | -5.58M | -34.48M | -76.85M | Operating Cash Flow |
| -21.26M | -15.39M | -5.32M | -29.56M | -48.59M | Investing Cash Flow |
| -3.80M | -3.51M | 395.00K | -11.79M | -19.44M | Financing Cash Flow |
| -145.00K | -251.00K | 52.39M | 8.04M | 52.28M |
Charlotte's Web Holdings Technical Analysis
Negative
0.12
Price Trends
0.12
Positive
0.13
Negative
0.16
Negative
Market Momentum
<0.01
Negative
48.06
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CWEB, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.12, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.06 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CWEB.
Charlotte's Web Holdings Risk Analysis
Charlotte's Web Holdings disclosed 84 risk factors in its most recent earnings report. Charlotte's Web Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Charlotte's Web Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
51 Neutral | $21.41M | ― | -78.03% | ― | -11.84% | 20.29% | |
| $17.97M | ― | -13.58% | ― | ― | ― | ||
| $21.52M | ― | -2.68% | ― | ― | ― | ||
| $24.40M | ― | -24.12% | ― | ― | ― | ||
| $21.64M | ― | -203.40% | ― | ― | ― | ||
44 Neutral | C$26.31M | ― | -31.24% | ― | 44.21% | 21.93% |
* Healthcare Sector Average
Performance Comparison
TSE:CWEB
Charlotte's Web Holdings
0.13
-0.09
-41.86%
CXXIF
C21 Investments
0.16
-0.11
-40.74%
ROMJF
Rubicon Organics
0.32
-0.05
-13.51%
VEXTF
Vext Science
0.09
-0.09
-50.00%
AVCNF
Avicanna
0.17
0.00
0.00%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.20
-0.06
-23.08%
Charlotte's Web Holdings Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Charlotte’s Web Launches Brightside™: A New Era in Hemp-Derived THC Wellness
Positive
May 27, 2025
Charlotte’s Web Holdings has launched Brightside™, a new line of low-dose THC gummies aimed at enhancing wellness routines with precision and care. This product line, featuring rapid onset technology, caters to the growing demand for low-dose THC edibles and reflects the company’s commitment to innovation and evidence-based wellness. The launch coincides with a pivotal moment in the hemp industry, as consumer interest in THC products rises, and aligns with the company’s strategic focus on sustainable growth and trust-based innovation.
The most recent analyst rating on (TSE:CWEB) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Business Operations and StrategyFinancial Disclosures
Charlotte’s Web Holdings Sees Revenue Growth and Strategic Expansion in Q1 2025
Positive
May 14, 2025
Charlotte’s Web Holdings reported its first year-over-year revenue increase in over three years for Q1 2025, indicating positive traction from its transformation strategy. The company has upgraded its e-commerce platform, expanded its digital and retail presence, and improved operational efficiencies, including in-house gummy production. These initiatives, along with a reengineered cost structure, are expected to drive further growth and improve cash flow, positioning the company for sustained success.
The most recent analyst rating on (TSE:CWEB) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Charlotte’s Web Holdings Reports Strong 2024 Growth and Strategic Expansion
Positive
Mar 19, 2025
Charlotte’s Web Holdings reported substantial growth and cost optimization in 2024, achieving sequential quarterly revenue growth and reducing operating expenses by over $22.4 million. The company launched a new e-commerce platform, expanded retail partnerships, and introduced new product innovations, including functional mushroom gummies and CBD gel caps. These efforts, along with a transition to in-house manufacturing, have positioned the company for sustained growth in 2025. The company’s strategic initiatives have improved operational efficiencies and expanded its market reach, setting the stage for further growth in the botanical wellness industry.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.